Qualisure News Sort by Date Posted: Newest first Oldest first Search by Keywords: Search Clear Qualisure Diagnostics and Invitrocue Announce Strategic Collaboration to Advance RNA-Based Precision Oncology Across Singapore and ASEAN PRESS RELEASE Calgary, Canada and Singapore — 2026-08-21 Qualisure Diagnostics Inc. and Invitrocue today announced a strategic collaboration to introduce Thyroid GuidePx®, Qualisure’s RNA-based diagnostic for papillary thyroid cancer, to Singapore and the broader ASEAN region. The collaboration combines Qualisure’s expertise in RNA-based diagnostics with Invitrocue’s established capabilities in precision medicine, advanced laboratory services, and […] August 21, 2026 3 min read Thyroid GuidePx® is now cited in the 2025 ATA Guidelines. Thyroid GuidePx® is now cited in the 2025 ATA Guidelines. This recognition highlights the growing role of molecular classifiers in papillary thyroid cancer — providing patient-specific recurrence risk to guide treatment decisions. It’s a proud milestone for Qualisure Diagnostics and for precision oncology. And it’s just the beginning. We remain committed to generating the evidence […] November 6, 2025 1 min read Unique Thyroid Cancer Tests: New Hope Unveiled Exciting Development in Thyroid Cancer Treatment: The Clinical Trial Vanguard Features Executive Interview on Innovative Thyroid Cancer Tests. Special thanks to Moe Alsumidaie and The Clinical Trial Vanguard for sharing this insightful conversation with our CEO and Founder, Oliver Bathe. Explore the groundbreaking Thyroid GuidePx® test and its promising impact on transforming personalized cancer care. […] March 24, 2024 7 min read Oliver Bathe: Qualisure Diagnostics Developing State-Of-The-Art Diagnostic Tests That Help To Personalize Cancer Care See the full Made in CA Interview with Dr. Oliver Bathe MD, FRCSC, FACS Qualisure Diagnostics develops state-of-the-art diagnostic tests that help to personalize cancer care. Our first test, Thyroid GuidePx, was recently launched. Thyroid GuidePx is a test that determines the risk of recurrence after treatment of thyroid cancer. If the thyroid cancer has […] August 18, 2023 5 min read 2022 American Thyroid Association – Dr. Oliver Bathe October 19-23 2022. Dr. Oliver Bathe presented results from a study of 742 patients at the 2022 Annual Meeting of the American Thyroid Association. The study demonstrated that Thyroid GuidePx® has a 97% specificity in identifying patients with low-risk papillary thyroid cancer. This is much more accurate than the 80% specificity the conventional ATA risk […] November 2, 2022 1 min read Qualisure Diagnostics: An AICE-Validate Success Story CALGARY, ALBERTA, Recently Jon Hagan, Senior Business Partner in Marketing and Communications at Alberta Innovates, sat down with our CEO Dr. Oliver Bathe. Jon explored the Qualisure commercialization journey with Dr. Bathe and how Qualisure benefited from accessing Alberta Innovates’ Accelerating Innovations into Care (AICE) – Validate program, resulting in Qualisure’s recent launch of our thyroid […] September 21, 2022 1 min read No more posts to show
